234 related articles for article (PubMed ID: 9764850)
1. Antibody responses to melanoma/melanocyte autoantigens in melanoma patients.
Huang SK; Okamoto T; Morton DL; Hoon DS
J Invest Dermatol; 1998 Oct; 111(4):662-7. PubMed ID: 9764850
[TBL] [Abstract][Full Text] [Related]
2. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy.
Okamoto T; Irie RF; Fujii S; Huang SK; Nizze AJ; Morton DL; Hoon DS
J Invest Dermatol; 1998 Dec; 111(6):1034-9. PubMed ID: 9856813
[TBL] [Abstract][Full Text] [Related]
3. The immunogenic properties of human melanomas and melanoma-associated antigens recognized by cytotoxic T lymphocytes.
Zeuthen J; Dzhandzhugazyan K; Hansen MR; Kirkin AF
Bratisl Lek Listy; 1998; 99(8-9):426-34. PubMed ID: 9810766
[TBL] [Abstract][Full Text] [Related]
4. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen.
Hoon DS; Yuzuki D; Hayashida M; Morton DL
J Immunol; 1995 Jan; 154(2):730-7. PubMed ID: 7814879
[TBL] [Abstract][Full Text] [Related]
5. Development of a polynucleotide vaccine from melanoma antigen recognized by T cells-1 and recombinant protein from melanoma antigen recognized by T cells-1 for melanoma vaccine clinical trials.
Lee SW; Li H; Strong TV; Moore SE; Conry RM
J Immunother; 2000; 23(3):379-86. PubMed ID: 10838667
[TBL] [Abstract][Full Text] [Related]
6. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732
[TBL] [Abstract][Full Text] [Related]
7. Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma.
Tanaka M; Kaneda Y; Fujii S; Yamano T; Hashimoto K; Huang SK; Hoon DS
Mol Ther; 2002 Mar; 5(3):291-9. PubMed ID: 11863419
[TBL] [Abstract][Full Text] [Related]
8. Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization.
Surman DR; Irvine KR; Shulman EP; Allweis TM; Rosenberg SA; Restifo NP
J Immunol Methods; 1998 May; 214(1-2):51-62. PubMed ID: 9692858
[TBL] [Abstract][Full Text] [Related]
9. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas.
Chi DD; Merchant RE; Rand R; Conrad AJ; Garrison D; Turner R; Morton DL; Hoon DS
Am J Pathol; 1997 Jun; 150(6):2143-52. PubMed ID: 9176405
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
Prins RM; Odesa SK; Liau LM
Cancer Res; 2003 Dec; 63(23):8487-91. PubMed ID: 14679014
[TBL] [Abstract][Full Text] [Related]
11. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
[TBL] [Abstract][Full Text] [Related]
12. Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma.
Reynolds SR; Zeleniuch-Jacquotte A; Shapiro RL; Roses DF; Harris MN; Johnston D; Bystryn JC
Clin Cancer Res; 2003 Feb; 9(2):657-62. PubMed ID: 12576432
[TBL] [Abstract][Full Text] [Related]
13. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development.
Chen YT; Stockert E; Tsang S; Coplan KA; Old LJ
Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8125-9. PubMed ID: 7667256
[TBL] [Abstract][Full Text] [Related]
14. Human high molecular weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody MK2-23. Characterization of the immunogenicity in syngeneic hosts.
Chen ZJ; Yang H; Ferrone S
J Immunol; 1991 Aug; 147(3):1082-90. PubMed ID: 1861071
[TBL] [Abstract][Full Text] [Related]
15. The immune response to melanoma is limited by thymic selection of self-antigens.
Träger U; Sierro S; Djordjevic G; Bouzo B; Khandwala S; Meloni A; Mortensen M; Simon AK
PLoS One; 2012; 7(4):e35005. PubMed ID: 22506061
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA).
Kemp EH; Gawkrodger DJ; Watson PF; Weetman AP
Clin Exp Immunol; 1998 Dec; 114(3):333-8. PubMed ID: 9844040
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA
J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214
[TBL] [Abstract][Full Text] [Related]
18. Characterization of human anti-high molecular weight-melanoma-associated antigen single-chain Fv fragments isolated from a phage display antibody library.
Desai SA; Wang X; Noronha EJ; Kageshita T; Ferrone S
Cancer Res; 1998 Jun; 58(11):2417-25. PubMed ID: 9622083
[TBL] [Abstract][Full Text] [Related]
19. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection.
Schreurs MW; de Boer AJ; Figdor CG; Adema GJ
Cancer Res; 1998 Jun; 58(12):2509-14. PubMed ID: 9635569
[TBL] [Abstract][Full Text] [Related]
20. Expression of melanoma-associated antigens in melanoma cell cultures.
Urosevic M; Braun B; Willers J; Burg G; Dummer R
Exp Dermatol; 2005 Jul; 14(7):491-7. PubMed ID: 15946236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
